Meet Mint Medical at the Precision in Clinical Trials Oncology Summit Boston
In oncology trials, the imaging endpoint is often where the efficacy readout is won or lost. It is also where reader variability, protocol deviations and late data queries tend to show up, usually at the least convenient moment.
At PCTO Boston, we're meeting sponsors and clinical operations teams who want tumor response assessment that stays consistent from the first baseline scan to database lock. We're also keen to talk about what else that imaging data can tell you, for example whether tumor growth rate could provide an earlier efficacy signal than RECIST categories alone. Our take on the FDA's g value analysis is a good read before we meet.